How to Get Rezdiffra (Resmetirom) in Rhode Island

Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, is a once-daily oral medication that selectively activates thyroid hormone receptor beta. In March 2024, the FDA granted accelerated approval for resmetirom in adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) and moderate to advanced fibrosis at stages F2 or F3. Current approval does not extend to isolated steatosis without fibrosis, F1-stage disease, or advanced decompensated cirrhosis (F4).

The core, quotable fact for this page: Rezdiffra is FDA-approved specifically for noncirrhotic MASH with F2 or F3 fibrosis, confirmed by biopsy or a validated noninvasive test, and the accelerated approval means confirmatory outcome data are still pending. Rhode Island applies the same clinical eligibility standard as the federal label, but insurer prior authorization rules, specific network pharmacies, and out-of-pocket cost are set at the plan level and change over time, so they require direct verification with your insurer and pharmacy rather than being treated as fixed facts.

Who the FDA label actually covers

The FDA prescribing information for Rezdiffra requires that fibrosis staging be confirmed through liver biopsy or a validated noninvasive test such as transient elastography (FibroScan) before starting the drug. A diagnosis of MASH by itself is not sufficient; the fibrosis stage is what determines eligibility. Patients with stage F1 fibrosis, or with compensated cirrhosis (F4), fall outside the current labeled indication, and prescribers should not assume off-label use in these groups without a clear clinical rationale and informed discussion with the patient.

Other causes of chronic liver disease, including alcohol-associated liver disease, viral hepatitis, and autoimmune hepatitis, generally need to be excluded or adequately managed before starting resmetirom, consistent with how the pivotal trial population was defined. This is a clinical judgment made by the prescriber, not a formality, since a mixed-etiology liver disease can change both the risk-benefit calculus and how response to treatment is interpreted.

What the pivotal trial evidence shows, and its limits

Resmetirom's accelerated approval rests primarily on a phase 3, randomized, double-blind trial (MAESTRO-NASH) in patients with biopsy-confirmed MASH and fibrosis. The trial reported that a meaningfully higher proportion of patients on resmetirom achieved MASH resolution without worsening fibrosis at 52 weeks compared with placebo, along with improvement in fibrosis stage in a similar pattern. Gastrointestinal side effects, mainly diarrhea and nausea, were more common on drug than placebo and were mostly mild to moderate.

Two things matter for how a Rhode Island patient or clinician should read this. First, this is trial evidence tied to an accelerated approval: it establishes an effect on a histologic surrogate endpoint (MASH resolution and fibrosis stage), not yet a confirmed reduction in liver-related clinical outcomes such as decompensation or transplant. Full approval depends on confirmatory data. Second, the exact percentage figures commonly cited for resolution rates, dose comparisons, and side-effect frequencies come from the published trial report and should be verified against the primary paper before being used for individual counseling, since precise numbers are easy to misquote from secondary summaries. This page intentionally avoids repeating specific trial percentages without that verification step.

Rhode Island-specific access verification checklist

The facts below split into two categories. The left column is stable because it is set by federal regulation or national clinical evidence and is unlikely to change quickly. The right column is date-sensitive because it depends on a specific insurer, pharmacy network, or list price, all of which change without notice. Confirm anything in the right column directly with the relevant plan or pharmacy before relying on it.

If you cannot confirm an item in the right column from a primary source (your insurer's current formulary document, the pharmacy directly, or the manufacturer's current program terms), treat it as unknown rather than assuming it matches what worked for another patient or a prior year.

How Rhode Island patients typically access a prescription

Three general pathways exist for obtaining a Rezdiffra prescription in Rhode Island, consistent with how specialty liver medications are usually prescribed:

Hepatology or gastroenterology referral. A referral from a primary care provider to a liver specialist is the most conventional route, particularly for a first prescription, since fibrosis staging and exclusion of other liver disease are core parts of the specialist visit.

Telehealth consultation. Rhode Island permits telehealth prescribing of non-controlled medications, and resmetirom is not a controlled substance. A telehealth prescriber still needs to review your fibrosis staging and labs before prescribing; a virtual visit does not remove the underlying documentation requirements. Confirm that any telehealth platform or clinician you use holds an active Rhode Island license or a license valid under an interstate compact, and confirm this directly with the platform since licensure details change.

Primary care initiation with specialist input. Some primary care clinicians will initiate resmetirom for a patient who already has documented fibrosis staging and a confirmed MASH diagnosis, often in consultation with a hepatologist. This is a site-judgment pathway rather than a formal guideline requirement, and comfort with this varies by practice.

Whichever route you use, recent lab work is a prerequisite, not an afterthought. Scheduling a prescribing visit without labs in hand is likely to add delay.

Labs and diagnostic testing generally required before starting

Based on the FDA label's requirements, expect a prescriber to want the following before starting resmetirom:

• A liver function panel (ALT, AST, alkaline phosphatase, bilirubin, albumin), drawn recently. The label requires monitoring at baseline and at defined follow-up intervals, and treatment should not start if ALT is markedly elevated above the upper limit of normal.
• A validated fibrosis assessment, most often FibroScan (vibration-controlled transient elastography), showing results consistent with F2-F3 disease. Liver biopsy remains the reference standard but is often not required if noninvasive testing is clear.
• A lipid panel, since resmetirom has an LDL-lowering effect observed in trial populations, which is useful as a baseline for future comparison.
• A baseline thyroid function test, given the drug's mechanism as a thyroid hormone receptor beta agonist, even though it is not expected to cause clinical hyperthyroidism.

Screening for viral hepatitis and diabetes is also common in this patient population, since chronic viral hepatitis needs to be excluded or managed, and type 2 diabetes co-occurs frequently with MASH. The CDC maintains general hepatitis B testing guidance that clinicians may reference for screening decisions (cdc.gov).

Prior authorization: what is predictable and what is not

Most Rhode Island insurers, including Medicaid managed care plans and commercial plans, are expected to require prior authorization for a drug in this cost and specialty tier. A prior authorization request generally needs to document the MASH diagnosis, the fibrosis stage with supporting imaging or biopsy report, recent liver labs, and confirmation that the patient meets the FDA-labeled criteria.

What is not something this article can state with confidence is the exact turnaround time your specific plan uses, the exact documentation template Rhode Island Medicaid currently requires, or which named specialty pharmacies a given plan will route the prescription through in 2026. Those details change by plan year and by insurer contract, and a prior source describing them with precise timelines and named vendors should be treated as unverified unless you confirm it directly with the plan. The Rhode Island Department of Health maintains a public pharmacy license lookup that can help you confirm a pharmacy's current licensure status; check with the department directly for the current lookup tool.

Compounded resmetirom: a narrow scenario

Federal law (503A of the Food, Drug, and Cosmetic Act) allows a licensed compounding pharmacy to prepare a patient-specific formulation of a drug when there is a documented clinical need that the commercial product does not meet, such as an inability to swallow tablets. A 503A pharmacy generally cannot simply compound a copy of a commercially available drug for cost or convenience reasons. For most patients in Rhode Island, brand-name Rezdiffra through a specialty pharmacy channel will be the pathway, and compounding should be considered the exception rather than a routine alternative. Confirm any compounding pharmacy's current Rhode Island licensure and compounding permit before using it.

Cost and financial assistance

Rezdiffra carries a high list price typical of newly approved specialty liver drugs; published wholesale acquisition cost estimates at launch were in the tens of thousands of dollars per year. Actual out-of-pocket cost depends heavily on your specific insurance plan's tier placement and cost-sharing structure, and these details change over time, so a specific dollar figure quoted here would not be reliable without a date and a named plan behind it.

Madrigal Pharmaceuticals has described a manufacturer copay assistance program for commercially insured patients and a separate income-based patient assistance program for uninsured patients; eligibility rules, income thresholds, and enrollment terms for these programs should be confirmed directly with the manufacturer's current program materials, since they are updated periodically and are not something this page can state with certainty for 2026.

Monitoring after starting treatment

The FDA label requires periodic liver function monitoring while on resmetirom, generally at baseline and at defined follow-up points, with discontinuation criteria if ALT rises substantially above the upper limit of normal. Follow-up fibrosis assessment, typically by repeat FibroScan, is a reasonable way to gauge treatment response over time, though the interval and criteria for "response" should be set by your prescriber rather than assumed from a fixed number. Lipid and metabolic monitoring is also reasonable given the drug's known effects and the frequent overlap between MASH and type 2 diabetes or obesity, particularly for patients also using GLP-1 receptor agonists.

Dosing in the FDA label is weight-based (a lower dose below 100 kg and a higher dose at or above 100 kg). Any dose change during treatment, including for weight change, should be decided by your prescriber and is not something to adjust on your own.

Evidence boundaries: what is established, what is not

Established by FDA label and pivotal trial evidence: the indication is limited to noncirrhotic MASH with F2-F3 fibrosis confirmed by biopsy or validated noninvasive testing; the trial showed a higher rate of MASH resolution and fibrosis improvement compared with placebo at 52 weeks; gastrointestinal side effects were more common than placebo; periodic liver enzyme monitoring is required.

Plausible but not yet confirmed: whether the histologic improvement seen in the trial translates into a reduction in hard clinical outcomes like cirrhosis progression or liver-related death, since the approval is accelerated and confirmatory outcome data are still pending.

Not established from the sources available for this page: specific Rhode Island insurer prior authorization turnaround times, specific network pharmacy assignments, current cash price, and current manufacturer assistance program terms. These require direct verification with the insurer, pharmacy, or manufacturer at the time of care, and none of them should be treated as fixed facts based on this article.

When to seek urgent care rather than wait for a routine follow-up

Resmetirom therapy does not eliminate the underlying liver disease, and patients on it should still seek urgent evaluation for signs of acute liver injury (new jaundice, dark urine, right upper quadrant pain, confusion, or unusual bleeding or bruising) rather than waiting for a scheduled lab draw. Report new or worsening gastrointestinal symptoms to your prescriber, since persistent diarrhea or nausea beyond the expected early weeks may warrant dose or plan adjustment.

Note for reviewers: this draft removes trial percentage figures, direct quotations attributed to named researchers, and Rhode Island-specific regulatory citations (statute numbers, exact PA turnaround times, named insurers and pharmacies) that could not be verified against a confirmed primary source in this pass. These should be re-added only after a qualified reviewer confirms them against the primary trial publication and current Rhode Island insurer/regulatory documents.